{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:58:14Z","timestamp":1781607494387,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People with opioid agonist therapy (OAT) represent a population with an increased hepatitis C (HCV) prevalence. Recent studies provide strong evidence regarding effective HCV treatment outcomes and low levels of reinfection in this population. Increased access to HCV care for people with OAT is essential to reach the WHO goal of eliminating HCV as a major public health threat by 2030.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Maria OAT clinic, located in central Stockholm, provides OAT for approximately 500 patients. The majority have a history of injection drug use. In October 2017, psychiatrist-led HCV treatment was initiated, with remote consultation support from the local infectious diseases clinic. All OAT staff participated in HCV-specific education to increase HCV awareness. To evaluate HCV treatment outcomes for this model of care, we examined sustained virological response (SVR) and reinfection rates between January 2018 and December 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between October 2017 and June 2022, 133 participants received HCV treatment through weekly administrations or directly observed treatment. 72% were men, and the overall mean age was 44.7 years. Six participants were retreated, giving a total of 139 treatment initiations. All were HCV RNA negative at end of treatment, and 88% reached SVR. A total of 11 reinfections post SVR were noted, with a reinfection rate of 7.3\/100 person-years (95% CI 4.1\u201312.9).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, successful HCV treatment results and levels of reinfections consistent with the literature were achieved. Bringing HCV diagnostics and treatment to an OAT clinic constitutes a good example of enhancing the HCV continuum of care. Furthermore, HCV treatment education for psychiatrists, addiction specialists and staff at OAT clinics makes HCV care more sustainable, as specifically noted during the COVID-19 pandemic. This successful model of care, introducing HCV treatment by psychiatrists on-site at OAT clinics, has now been further implemented at other OAT clinics in Stockholm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-025-06733-3","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T11:01:41Z","timestamp":1743073301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Psychiatrist-led hepatitis C (HCV) treatment at an opioid agonist treatment clinic in Stockholm\u2013 a model to enhance the HCV continuum of care"],"prefix":"10.1186","volume":"25","author":[{"given":"Per-Erik","family":"Klasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Sandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6643-3245","authenticated-orcid":false,"given":"Martin","family":"K\u00e5berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"6733_CR1","unstructured":"WHO, Hepatitis C. 2024 2024\/11\/22]; Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"issue":"9","key":"6733_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.7326\/M18-1715","volume":"170","author":"MJ Akiyama","year":"2019","unstructured":"Akiyama MJ, et al. Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: A randomized controlled trial. Ann Intern Med. 2019;170(9):594\u2013603.","journal-title":"Ann Intern Med"},{"issue":"11","key":"6733_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","volume":"3","author":"B Hajarizadeh","year":"2018","unstructured":"Hajarizadeh B, et al. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(11):754\u201367.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"6733_CR4","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1093\/cid\/ciz696","volume":"70","author":"C Graf","year":"2020","unstructured":"Graf C, et al. Efficacy of Direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: A systematic review and Meta-analysis. Clin Infect Dis. 2020;70(11):2355\u201365.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"6733_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/cid\/ciz384","volume":"70","author":"S Gutkind","year":"2020","unstructured":"Gutkind S, et al. Cost-effectiveness of hepatitis C virus treatment models for people who inject drugs in opioid agonist treatment programs. Clin Infect Dis. 2020;70(7):1397\u2013405.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"6733_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","volume":"72","author":"B Hajarizadeh","year":"2020","unstructured":"Hajarizadeh B, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. J Hepatol. 2020;72(4):643\u201357.","journal-title":"J Hepatol"},{"key":"6733_CR7","unstructured":"WHO. Combating hepatitis B and C to reach elimination to 2030. 2016."},{"key":"6733_CR8","unstructured":"WHO. Global health sector strategy on viral hepatitis 2016\u20132021, towards ending viral hepatitis. Geneva; 2016."},{"key":"6733_CR9","unstructured":"WHO. Interim guidance for country validation of viral hepatitis elimination. 2021."},{"key":"6733_CR10","unstructured":"WHO. Validation of viral hepatitis elimination and path to elimination: technical report. 2023."},{"key":"6733_CR11","unstructured":"Swedish Government Inqueries. Vi kan b\u00e4ttre! Kunskapsbaserad narkotikapolitik med liv och h\u00e4lsa i fokus [We can do better! Knowledge-based drugs policy focused on life and health], SOU 2023:62. 2023."},{"issue":"3","key":"6733_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/add.14012","volume":"113","author":"L Platt","year":"2018","unstructured":"Platt L, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane review and meta-analysis. Addiction. 2018;113(3):545\u201363.","journal-title":"Addiction"},{"issue":"5","key":"6733_CR13","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1016\/S2214-109X(23)00058-X","volume":"11","author":"S Colledge-Frisby","year":"2023","unstructured":"Colledge-Frisby S, et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(5):e673\u201383.","journal-title":"Lancet Glob Health"},{"issue":"8","key":"6733_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/23744235.2017.1300682","volume":"49","author":"M Lagging","year":"2017","unstructured":"Lagging M, et al. Treatment of hepatitis C virus infection: updated Swedish guidelines 2016. Infect Dis (Lond). 2017;49(8):561\u201375.","journal-title":"Infect Dis (Lond)"},{"key":"6733_CR15","unstructured":"RAV, [Referensgruppen f\u00f6r antiviral terapi], Treatment of hepatitis C virus infection in adults and children 2023\u2013 Treatment recommendation, [L\u00e4kemedelsbehandling av hepatit C-virusinfektion hos vuxna och barn 2023\u2013 Behandlingsrekommendation]. 2023; Available from: https:\/\/www.sls.se\/globalassets\/rav\/rekommendationer\/hcv-rek-230524.pdf"},{"issue":"11","key":"6733_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","volume":"14","author":"J Grebely","year":"2017","unstructured":"Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol. 2017;14(11):641\u201351.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"6733_CR17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1473-3099(16)30208-0","volume":"16","author":"K Zhou","year":"2016","unstructured":"Zhou K, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis. 2016;16(12):1409\u201322.","journal-title":"Lancet Infect Dis"},{"key":"6733_CR18","doi-asserted-by":"publisher","first-page":"103917","DOI":"10.1016\/j.drugpo.2022.103917","volume":"111","author":"EB Cunningham","year":"2023","unstructured":"Cunningham EB, et al. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis. Int J Drug Policy. 2023;111:103917.","journal-title":"Int J Drug Policy"},{"key":"6733_CR19","unstructured":"WHO. Global Hepatitis Report, 2017. 2017."},{"issue":"1","key":"6733_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/liv.13949","volume":"39","author":"E Day","year":"2019","unstructured":"Day E, et al. Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework. Liver Int. 2019;39(1):20\u201330.","journal-title":"Liver Int"},{"issue":"9","key":"6733_CR21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/00365540903062143","volume":"41","author":"C Lidman","year":"2009","unstructured":"Lidman C, et al. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis. 2009;41(9):679\u201384.","journal-title":"Scand J Infect Dis"},{"issue":"5","key":"6733_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/MEG.0000000000000076","volume":"26","author":"A Jerkeman","year":"2014","unstructured":"Jerkeman A, et al. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy. Eur J Gastroenterol Hepatol. 2014;26(5):523\u201331.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"6733_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3109\/00365548.2013.879994","volume":"46","author":"A Jerkeman","year":"2014","unstructured":"Jerkeman A, et al. Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy\u2013factors associated with advanced fibrosis. Scand J Infect Dis. 2014;46(5):340\u20137.","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"6733_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13011-020-00286-2","volume":"15","author":"CF Aas","year":"2020","unstructured":"Aas CF, et al. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy. 2020;15(1):44.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"9","key":"6733_CR25","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1111\/liv.14978","volume":"41","author":"S Blach","year":"2021","unstructured":"Blach S, et al. Hepatitis C elimination in Sweden: progress, challenges and opportunities for growth in the time of COVID-19. Liver Int. 2021;41(9):2024\u201331.","journal-title":"Liver Int"},{"issue":"6","key":"6733_CR26","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/liv.15266","volume":"42","author":"H Midgard","year":"2022","unstructured":"Midgard H, et al. Peer support in small towns: A decentralized mobile hepatitis C virus clinic for people who inject drugs. Liver Int. 2022;42(6):1268\u201377.","journal-title":"Liver Int"},{"issue":"10","key":"6733_CR27","doi-asserted-by":"publisher","first-page":"101145","DOI":"10.1016\/j.jhepr.2024.101145","volume":"6","author":"A Herranz Mochales","year":"2024","unstructured":"Herranz Mochales A, et al. Implementing a new HCV model of care for people who use drugs. JHEP Rep. 2024;6(10):101145.","journal-title":"JHEP Rep"},{"key":"6733_CR28","doi-asserted-by":"crossref","unstructured":"Conway A et al. A testing campaign intervention consisting of Peer-Facilitated engagement, Point-of-Care HCV RNA testing, and linkage to nursing support to enhance hepatitis C treatment uptake among people who inject drugs: the ETHOS engage study. Viruses, 2022. 14(7).","DOI":"10.3390\/v14071555"},{"key":"6733_CR29","doi-asserted-by":"crossref","unstructured":"Yi S, et al. Community Pop-Up Clinic: Cascade of Care and HCV Treatment of Vancouver\u2019s Inner-City PWID Populations. J Viral Hepat; 2024.","DOI":"10.1111\/jvh.14023"},{"key":"6733_CR30","doi-asserted-by":"publisher","first-page":"104185","DOI":"10.1016\/j.drugpo.2023.104185","volume":"121","author":"J Demant","year":"2023","unstructured":"Demant J, et al. Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark. Int J Drug Policy. 2023;121:104185.","journal-title":"Int J Drug Policy"},{"key":"6733_CR31","unstructured":"Sveriges Kommuner och Regioner, National Elimination Plan - Plan for the elimination of hepatitis C [Nationell elimineringsplan - Plan f\u00f6r eliminering av hepatit C]. 2022."},{"key":"6733_CR32","unstructured":"K\u00e5berg M, Makarova N. Insufficicient HCV testing in an OAT clinic in Stockholm calls for changes in testing routines. Poster presentation, Nordic HIV and Virology Conference, Stockholm. 2017."},{"key":"6733_CR33","unstructured":"Hepatitis C. in Primary Care and Drug and Alcohol Settings Education Program, International Network on Health and Hepatitis in Substance Users (INHSU). 2023 2023-08-16]; Available from: https:\/\/www.inhsu.org\/what-we-do\/education\/"},{"key":"6733_CR34","unstructured":"Habraken N, Dawson DE, Valerio O, Leber H, Pesava B, Runk C, Aghemo L, Dillon A, K\u00e5berg J, Lacombe M, Lazarus K, Marinho JV, Moriggia RT, \u00d8vrehus A, Reimer A, Shah J, Torrens H, Lloyd M, Grebely A. J, Enhanced self-efficacy for HCV management amongst participants of an HCV education program in drug & alcohol settings, Poster presentation, World Hepatitis Summit Conference 2022, Gen\u00e8ve. 2022."},{"key":"6733_CR35","unstructured":"Hepatitis CR. Consultation Request for Initiation of Hepatitis C Treatment, GESA-Australian Liver Association. 2023 2023\/08\/15]; Available from: https:\/\/insight.qld.edu.au\/shop\/hepatitis-c-remote-consultation-request-for-initiation-of-hepatitis-c-treatment"},{"key":"6733_CR36","unstructured":"Drug Interactions HEP., University of Liverpool. 2023 2023\/08\/15]; Available from: https:\/\/www.hep-druginteractions.org"},{"issue":"3","key":"6733_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/00365521.2019.1580764","volume":"54","author":"M Kaberg","year":"2019","unstructured":"Kaberg M, et al. Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm needle Exchange - evaluated with liver elasticity. Scand J Gastroenterol. 2019;54(3):319\u201327.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"6733_CR38","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","volume":"48","author":"L Castera","year":"2008","unstructured":"Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835\u201347.","journal-title":"J Hepatol"},{"issue":"7","key":"6733_CR39","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00228-018-2456-y","volume":"74","author":"P Frisk","year":"2018","unstructured":"Frisk P, et al. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. Eur J Clin Pharmacol. 2018;74(7):971\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"6733_CR40","doi-asserted-by":"publisher","first-page":"e0217471","DOI":"10.1371\/journal.pone.0217471","volume":"14","author":"PO Coffin","year":"2019","unstructured":"Coffin PO, et al. Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs. PLoS ONE. 2019;14(6):e0217471.","journal-title":"PLoS ONE"},{"key":"6733_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.drugpo.2019.06.016","volume":"72","author":"J Valencia","year":"2019","unstructured":"Valencia J, et al. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Int J Drug Policy. 2019;72:181\u20138.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"6733_CR42","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.7326\/M21-4119","volume":"175","author":"J Grebely","year":"2022","unstructured":"Grebely J, et al. Reinfection and risk behaviors after treatment of hepatitis C virus infection in persons receiving opioid agonist therapy: A cohort study. Ann Intern Med. 2022;175(9):1221\u20139.","journal-title":"Ann Intern Med"},{"key":"6733_CR43","doi-asserted-by":"publisher","first-page":"103418","DOI":"10.1016\/j.drugpo.2021.103418","volume":"96","author":"M Selfridge","year":"2021","unstructured":"Selfridge M, et al. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada. Int J Drug Policy. 2021;96:103418.","journal-title":"Int J Drug Policy"},{"key":"6733_CR44","doi-asserted-by":"crossref","unstructured":"Lindqvist K, Thorin Z, K\u00e5berg M. Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden. Harm reduct J, 2023. 20(1): p. 72.","DOI":"10.1186\/s12954-023-00801-1"},{"key":"6733_CR45","doi-asserted-by":"crossref","unstructured":"Dore GJ. HCV reinfection as a positive indication of high-risk population treatment access. J Viral Hepat; 2019.","DOI":"10.1111\/jvh.13092"},{"key":"6733_CR46","doi-asserted-by":"publisher","first-page":"104433","DOI":"10.1016\/j.drugpo.2024.104433","volume":"128","author":"C Gahrton","year":"2024","unstructured":"Gahrton C, et al. Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era. Int J Drug Policy. 2024;128:104433.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"6733_CR47","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1186\/s12913-023-09777-x","volume":"23","author":"MA Corcorran","year":"2023","unstructured":"Corcorran MA, et al. Training the healthcare workforce to support task-shifting and viral hepatitis elimination: a global review of english Language online trainings and in-person workshops for management of hepatitis B and C infection. BMC Health Serv Res. 2023;23(1):849.","journal-title":"BMC Health Serv Res"},{"key":"6733_CR48","doi-asserted-by":"publisher","first-page":"103588","DOI":"10.1016\/j.drugpo.2022.103588","volume":"102","author":"T Schwarz","year":"2022","unstructured":"Schwarz T, et al. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. Int J Drug Policy. 2022;102:103588.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"6733_CR49","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1186\/s12913-023-09849-y","volume":"23","author":"MA Corcorran","year":"2023","unstructured":"Corcorran MA, et al. Training the healthcare workforce: the global experience with telementorship for hepatitis B and hepatitis C. BMC Health Serv Res. 2023;23(1):824.","journal-title":"BMC Health Serv Res"},{"key":"6733_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugpo.2018.08.011","volume":"61","author":"S Bajis","year":"2018","unstructured":"Bajis S, et al. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. Int J Drug Policy. 2018;61:23\u201330.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"6733_CR51","doi-asserted-by":"publisher","first-page":"ofac225","DOI":"10.1093\/ofid\/ofac225","volume":"9","author":"B Eckhardt","year":"2022","unstructured":"Eckhardt B, et al. Rapid treatment initiation for hepatitis C in young people who inject drugs: the seek, test, and rapid treatment randomized trial. Open Forum Infect Dis. 2022;9(7):ofac225.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"6733_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","volume":"74","author":"S Blach","year":"2021","unstructured":"Blach S, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74(1):31\u20136.","journal-title":"J Hepatol"}],"updated-by":[{"DOI":"10.1186\/s12888-025-07203-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000}}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06733-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06733-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06733-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:42:14Z","timestamp":1781606534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-025-06733-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6733"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06733-3","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"3 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12888-025-07203-6","URL":"https:\/\/doi.org\/10.1186\/s12888-025-07203-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Helsinki Declaration and was approved by the Regional Ethical Review Board in Stockholm (Dnr: 2019\u2009\u2212\u2009002016). All HCV treated participants at the Maria OAT clinic were informed about the study and provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PEK has received honoraria for lectures from Gilead and Indivior; SA has received payment or honoraria for lectures and educational events from Gilead, AbbVie, Merck Sharp & Dohme, Biogen, not related to this work; MK has received honoraria for lectures\/consultancy from AbbVie, Gilead, MSD, Mundipharma, DnE Pharma, Nordic Drugs and has received research grants from Gilead and Nordic Drugs. No conflicts of interest exist for the remaining author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"291"}}